Download PDF
Thromb Haemost 2000; 83(04): 563-570
DOI: 10.1055/s-0037-1613864
Commentary
Schattauer GmbH

The Role of Vitamin B12 in Fasting Hyperhomocysteinemia and Its Interaction with the Homozygous C677T Mutation of the Methylenetetrahydrofolate Reductase (MTHFR) Gene

A Case-control Study of Patients with Early-onset Thrombotic Events
Armando D’Angelo
1   From the Coagulation Service and Thrombosis Research Unit, Milan, Italy
,
Antonio Coppola
2   Department of Clinical and Experimental Medicine, University of Naples “Federico II”, Naples, Italy
,
Pasquale Madonna
2   Department of Clinical and Experimental Medicine, University of Naples “Federico II”, Naples, Italy
,
Isabella Fermo
3   Department of Laboratory Medicine, Milan, Italy
,
Anna Pagano
2   Department of Clinical and Experimental Medicine, University of Naples “Federico II”, Naples, Italy
,
Giuseppina Mazzola
1   From the Coagulation Service and Thrombosis Research Unit, Milan, Italy
,
Laura Galli
4   Epidemiology Unit, I.R.C.C.S. H. S. Raffaele, Milan, Italy
,
Anna Maria Cerbone
2   Department of Clinical and Experimental Medicine, University of Naples “Federico II”, Naples, Italy
› Author AffiliationsThis work was partly supported by CNR grants (97.00472.CT04) and from Telethon-Italy (no. E.C.804).
Further Information

Publication History

Received 11 August 1999

Accepted after resubmission 14 December 1999

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Total fasting plasma homocysteine (tHcy), homozygosity for the C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene and for the A2756G mutation of the methionine synthase (MS) gene, vitamin B12 and folate plasma levels were evaluated in 170 consecutive patients (89 M, 81 F; mean age 41 ± 12 yrs) with documented early-onset thrombosis (89 venous, 69 arterial, 12 both; mean age at first episode 36 ± 11 yrs), and in 182 age- and sex-matched healthy control subjects. Moderate hyperhomocysteinemia (HHcy, tHcy >19.5 µM in men and >15 µM in women) was detected in 45 patients (26.5%) and in 18 controls (9.9%, Mantel-Haenszel OR and 95% C.I. after stratification for arterial or venous thrombosis: 3.25, 1.78–5.91). The 677TT MTHFR genotype was not significantly more prevalent in patients (27.6%) than in controls (21.4%, RR = 1.42; 0.84–2.41), and markedly contributed to HHcy (Mantel-Haenszel RR after stratification for case/control status: 8.29, 4.61–14.9). The 2756GG MS genotype, observed in 4 patients (2.4%) and 8 controls (4.4%), was not associated to HHcy. tHcy was negatively correlated to folate and vitamin B12 levels, with better correlation found in subjects with the 677TT mutation (r = −0.42 and −0.25) than with the 677CC or CT MTHFR genotype (r = −0.37 and −0.11). However, folate was similar in patients and controls and vitamin B12 was higher in patients (460 ± 206 vs. 408 ± 185 pg/ml, p = 0.011). In a generalized linear model, 44% of the variation in tHcy levels was explained by folate and vitamin B12 levels, the MTHFR genotype, gender, and by the interaction of the MTHFR genotype with folate (p ≤0.028); the interactions of vitamin B12 with the MTHFR genotype, gender and patient/control status also significantly contributed to the variation in tHcy levels (p ≤0.028). A 4-week administration of 5-methyltetrahydrofolate (15 mg/day) markedly lowered plasma tHcy in 24 patients with MTHFR 677TT genotype, but the response to treatment correlated with vitamin B12 levels (p = 0.023). Subjects carrying the MTHFR 677TT genotype have higher folate and vitamin B12 requirements irrespective of the A2756G polymorphism of the MS gene. Yet unidentified abnormalities of MS or of any of the enzymes participating in the synthesis of methylated vitamin B12 may play an important role in the phenotypic expression of moderate hyperhomocysteinemia.

Keywords

Hyperhomocysteinemia - folate - Vitamin B12 5,10-methylenetetrahydrofolate reductase - methionine synthase - juvenile thrombosis
 

  • References

  • 1 Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
    CrossrefPubMedGoogle Scholar
  • 2 Boers GHJ. Hyperhomocysteinemia as a risk factor for arterial and venous disease. A review of evidence and relevance. Thromb Haemost 1997; 78: 520-2.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 D’Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
    PubMedGoogle Scholar
  • 4 Pancharuniti N, Lewis CA, Sauberlich HE, Perkins LL, Rodney CP, Alvarez JO, Macaluso M, Acton RT, Copeland RB, Cousins AL, Gore TB, Cornwell PE, Roseman JM. Plasma homocyst(e)ine, folate and vitamin B12 concentrations and risk of early-onset coronary artery disease. Am J Clin Nutr 1994; 59: 940-8.
    CrossrefPubMedGoogle Scholar
  • 5 Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocysteinemia in patients with juvenile venous thrombosis. Arterioscl Thromb 1994; 14: 1080-3.
    CrossrefPubMedGoogle Scholar
  • 6 Fermo I, Vigano’ D’ Angelo S, Paroni R, Mazzola G, Calori G, D’Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with earlyonset venous and arterial thrombosis. Ann Intern Med 1995; 123: 747-53.
    CrossrefPubMedGoogle Scholar
  • 7 Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Medicine 1998; 49: 31-62.
    PubMedGoogle Scholar
  • 8 Kang SS, Wong PWK. Genetic and non-genetic factors for moderate hyperhomocysteinemia. Atherosclerosis 1994; 119: 135-8.
    PubMedGoogle Scholar
  • 9 Skovby F. Inborn errors of metabolism causing homocysteinemia and related vascular involvement. Haemostasis 1989; 19 (Suppl. 01) 4-9.
    PubMedGoogle Scholar
  • 10 Kang SS, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-21.
    PubMedGoogle Scholar
  • 11 Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995; 10: 111-3.
    CrossrefPubMedGoogle Scholar
  • 12 Selhub J, D’Angelo A. Relationship between homocysteine and thrombotic disease. Am J Med Sci 1998; 316: 129-41.
    PubMedGoogle Scholar
  • 13 Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81: 165-76.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Kang SS, Wong PWK, Bock HO, Horowitz A, Grix A. Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet 1991; 48: 546-51.
    PubMedGoogle Scholar
  • 15 Miller JW, Ribaya-Mercado JD, Russell RM, Shepard DC, Morrow FD, Cochary EF, Sadowsky JA, Gershoff SN, Sehlub J. Effect of vitamin B6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 1992; 55: 1154-60.
    CrossrefPubMedGoogle Scholar
  • 16 Selhub J, Jacques PF, Wilson PWF, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in the elderly. JAMA 1993; 270: 2693-8.
    CrossrefPubMedGoogle Scholar
  • 17 Lindenbaum J, Rosenberg IH, Wilson PWF, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994; 60: 2-11.
    CrossrefPubMedGoogle Scholar
  • 18 Kang SS, Wong PWK, Norusis M. Homocysteinemia due to folate deficiency. Metabolism 1987; 36: 458-62.
    CrossrefPubMedGoogle Scholar
  • 19 Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindebaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 1988; 81: 466-74.
    CrossrefPubMedGoogle Scholar
  • 20 Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1995; 15: 1314-20.
    CrossrefPubMedGoogle Scholar
  • 21 Verhoef P, Kok FJ, Kruyssen DACM, Schouten EG, Witteman CM, Grobbee DE, Ueland PM, Refsum H. Plasma total homocysteine, B vitamins and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 989-95.
    CrossrefPubMedGoogle Scholar
  • 22 Jacques PF, Bostom AG, Williams RR. et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentration. Circulation 1996; 93: 7-9.
    CrossrefPubMedGoogle Scholar
  • 23 Ma J, Stampfer MJ, Hennekens CH, Frosst P, Sehlub J, Horshford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-6.
    CrossrefPubMedGoogle Scholar
  • 24 Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, Psaty BM, Longstreth WT, Koepsell TD, Raghunathan TE, Reitsma PH. Myocardial infarction in young women in relation to plasma total homocysteine, folate and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96: 412-7.
    CrossrefPubMedGoogle Scholar
  • 25 Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt D, Genst J, Rozen R. Correlation of a common mutation in the methylenetetrahydrofolate reductase (MTHFR) gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscl Thromb Vasc Biol 1997; 17: 569-73.
    CrossrefPubMedGoogle Scholar
  • 26 Verhoef P, Kok FJ, Kluijtmans LA, Blom HJ, Refsum H, Ueland PM, Kruyssen DA. The 677C→T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 1997; 13: 105-13.
    PubMedGoogle Scholar
  • 27 Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, Faccini G, Pignatti PF, Mazzucco A, Corrocher R. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from Northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998; 91: 4158-63.
    CrossrefPubMedGoogle Scholar
  • 28 Guttormsen AB, Ueland PM, Nesthus I, Nygard O, Schneede J, Vollset SE, Refsum H. Determinants and vitamin responsiveness of intermediate HHcy (2≥40 µmol/liter). J Clin Invest 1996; 98: 2174-83.
    CrossrefPubMedGoogle Scholar
  • 29 Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, Eydoux P, Rosenblatt DS, Rozen R, Gravel RA. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996; 05: 1867-74.
    CrossrefPubMedGoogle Scholar
  • 30 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988; 16: 1215.
    CrossrefPubMedGoogle Scholar
  • 31 de Franchis R, Mancini FP, D’Angelo A, Sebastio G, Fermo I, De Stefano V, Margaglione M, Mazzola G, Di Minno G, Andria G. Elevated total plasma homocysteine and 677C->T mutation of the 5,10 methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet 1996; 59: 262-4.
    PubMedGoogle Scholar
  • 32 Fermo I, Arcelloni C, De Vecchi E, Viganò D’Angelo S, D’Angelo A, Paroni R. High-performance liquid chromatografic method with fluorescence detection for the determination of total homocyst(e)ine in plasma. J Chromatogr 1992; 593: 171-6.
    CrossrefPubMedGoogle Scholar
  • 33 Kluijtmans LAJ, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep vein thrombosis. Thromb Haemost 1998; 79: 254-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
    PubMedGoogle Scholar
  • 35 Kluijtmans LAJ, Kastelein JJP, Lindemans J, Boers GHJ, Heil SG, Bruschke AVG, Jukema JV, van den Heuvel LPWJ, Trijbels FJM, Boerma GJM, Verheugt FWA, Willems F, Blom HJ. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1997; 96: 2573-7.
    CrossrefPubMedGoogle Scholar
  • 36 Brattström L. Common mutation in the methylenetetrahydrofolate reducytase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. Circulation 1997; 96: 3805-6.
    PubMedGoogle Scholar
  • 37 D’Angelo A, Beltrametti C. Venous disease. In “Homocysteine in Health and Disease”. Carmel R, Jacobsen DW. eds Cambridge University Press; New York: 1999. in press.
    Google Scholar
  • 38 Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. for the MRFIT Research Group. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
    CrossrefPubMedGoogle Scholar
  • 39 Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, Hess DL, Davis CE. Prospective study of coronary heart disease incidence in relation to fasting homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998; 98: 204-10.
    CrossrefPubMedGoogle Scholar
  • 40 Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. on behalf of the EARS group. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. Atherosclerosis 1998; 136: 347-54.
    CrossrefPubMedGoogle Scholar
  • 41 den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinemia a risk factor for recurrent thrombosis?. Lancet 1995; 345: 882-5.
    CrossrefPubMedGoogle Scholar
  • 42 Deloughery TG, Evans A, Sadeghi A, McWilliams J, Henner D, Taylor Jr LM, Press RD. Common mutation in methylenetetrahydrofolate reductase: correlation with homocysteine metabolism and late-onset vascular disease. Circulation 1996; 94: 3074-8.
    CrossrefPubMedGoogle Scholar
  • 43 Brattström L. Vitamins as homocysteine lowering agents. J Nutr 1996; 126: 1276S-80S.
    CrossrefPubMedGoogle Scholar
  • 44 Malinow MR, Nieto FJ, Kruger WD, Duell PB, Hess DL, Gluckman RA, Block PC, Holzgang CR, Anderson PH, Seltzer D, Upson B, Lin QR. The effects of folic acid supplementation on plasma homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscl Thromb Vasc Biol 1997; 17: 1157-62.
    CrossrefPubMedGoogle Scholar
  • 45 den Heijer M, Brower IA, Bos GM, Blom HJ, van der Put NM, Spaans AP, Rosendaal FR, Thomas CM, Haak HL, Wijermans PW, Gerrits WB. Vitamin supplementation reduces blood homocysteine levels. A controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998; 18: 356-61.
    CrossrefPubMedGoogle Scholar
  • 46 Verhoef P, Klujitmans LAJ, Blom HJ, Kok FJ. The A2756G mutation in the gene coding for methionine synthase: associations with plasma homocysteine and coronary atherosclerosis. Ned J Med 1998; 52: S52.
    PubMedGoogle Scholar
  • 47 Morita H, Kurihara H, Sugiyama T, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y. Polymorphism of the methionine synthase gene: association with homocysteine metabolism and late-onset vascular disease in the japanese population. Arterioscl Thromb Vasc Biol 1999; 19: 298-302.
    CrossrefPubMedGoogle Scholar
  • 48 Levy HL, Mudd SH, Schulman JD, Dryefus PM, Abeles RH. A derangement in B12 metabolism associated with homocystinemia, cystathioninemia, hypomethioninemia and methylmalonic aciduria. Am J Med 1970; 48: 390-7.
    CrossrefPubMedGoogle Scholar
  • 49 Goodman SI, Moe PG, Hammond KB, Mudd SH, Uhlendorf BW. Homocystinuria with methylmalonic aciduria: two cases in a sibship. Biochem Med 1970; 04: 500-15.
    CrossrefPubMedGoogle Scholar
  • 50 Mudd SH, Levy HL, Morrow G. Deranged B12 metabolism: effects on sulfur amino acid metabolism. Biochem Med 1970; 04: 193-214.
    CrossrefPubMedGoogle Scholar
  • 51 Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P, Rubba P, Palma-Reis R, Meleady R, Daly L, Witteman J, Graham I. for the European COMAC Group. Low circulating folate and vitamin B6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary heart disease. Circulation 1998; 97: 437-43.
    CrossrefPubMedGoogle Scholar
  • 52 de Franchis R, Fermo I, Mazzola G, Sebastio G, Di Minno G, Coppola A, Galli L, Buoniconti A, Andria A, D’Angelo A. A common mutation of the cystathionine β-synthase gene (844INS68) is a risk factor for early-onset thrombosis and a determinant of fasting hyperhomocysteinemia only when associated to the thermolabile variant of methylenetetrahydrofolate reductase. Blood 1998; 92 (Suppl. 01) 560a.
    PubMedGoogle Scholar